Jennifer D Hosford1, Michael E von Fricken2, Michael Lauzardo1, Myron Chang3, Yunfeng Dai3, Jennifer A Lyon4, John Shuster5, Kevin P Fennelly6. 1. Southeastern National Tuberculosis Center, Department of Medicine, University of Florida, Gainesville, FL, USA; Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA. 2. Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA; Department of Environmental and Global Health, University of Florida, Gainesville, FL, USA. 3. Department of Biostatistics, University of Florida, Gainesville, FL, USA. 4. Biomedical and Health Information Services, University of Florida, Gainesville, FL, USA. 5. Department of Health Outcomes and Policy, University of Florida, Gainesville, FL, USA. 6. Southeastern National Tuberculosis Center, Department of Medicine, University of Florida, Gainesville, FL, USA; Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA. Electronic address: Kevin.Fennelly@medicine.ufl.edu.
Abstract
BACKGROUND: Elderly persons have the highest rates of tuberculosis (TB) in the United States compared to all other age groups. A systematic literature review was conducted to determine if older age was a risk factor for hepatotoxicity resulting from treatment with first-line drugs used to treat active (TB) and latent tuberculosis (LTBI). METHODS: A systematic review of MEDLINE, Cochrane Controlled Trial Registry, CINAHL(®), and Science Citation Index Expanded (from 1970 to 2011) was performed to determine the risk of hepatotoxicity, comparing those over 60 with those under 60. A meta-analysis was performed using a random effects model along with log odds ratios and the chi-square test. FINDINGS: Thirty-eight studies (40,034 participants; 1208 cases of hepatotoxicity) met the selection criteria. For active TB, an overall mean effect of 0.277 (p = 0.024, 95% CI: 0.037-0.517) was observed, which is equivalent to an odds ratio of 1.32 (95% CI: 1.04-1.68). For LTBI, an overall mean effect of 1.42 (p < 0.001, 95% CI: 0.794-2.05) was observed, which translates to an odds ratio of 4.14 (95% CI: 2.21-7.74). INTERPRETATION: Our analysis revealed that patients older than 60 had significantly more risk of hepatotoxicity. These studies suggest that a gentler regimen of treatment for older individuals could benefit health outcomes in this population of TB patients and minimize risks to the public's health.
BACKGROUND: Elderly persons have the highest rates of tuberculosis (TB) in the United States compared to all other age groups. A systematic literature review was conducted to determine if older age was a risk factor for hepatotoxicity resulting from treatment with first-line drugs used to treat active (TB) and latent tuberculosis (LTBI). METHODS: A systematic review of MEDLINE, Cochrane Controlled Trial Registry, CINAHL(®), and Science Citation Index Expanded (from 1970 to 2011) was performed to determine the risk of hepatotoxicity, comparing those over 60 with those under 60. A meta-analysis was performed using a random effects model along with log odds ratios and the chi-square test. FINDINGS: Thirty-eight studies (40,034 participants; 1208 cases of hepatotoxicity) met the selection criteria. For active TB, an overall mean effect of 0.277 (p = 0.024, 95% CI: 0.037-0.517) was observed, which is equivalent to an odds ratio of 1.32 (95% CI: 1.04-1.68). For LTBI, an overall mean effect of 1.42 (p < 0.001, 95% CI: 0.794-2.05) was observed, which translates to an odds ratio of 4.14 (95% CI: 2.21-7.74). INTERPRETATION: Our analysis revealed that patients older than 60 had significantly more risk of hepatotoxicity. These studies suggest that a gentler regimen of treatment for older individuals could benefit health outcomes in this population of TB patients and minimize risks to the public's health.
Authors: Rohit Singla; Surendra K Sharma; Alladi Mohan; Govind Makharia; V Sreenivas; Brajesh Jha; Sanjeev Kumar; Pawan Sarda; Sarman Singh Journal: Indian J Med Res Date: 2010-07 Impact factor: 2.375
Authors: Dick Menzies; Richard Long; Anete Trajman; Marie-Josée Dion; Jae Yang; Hamdan Al Jahdali; Ziad Memish; Kamran Khan; Michael Gardam; Vernon Hoeppner; Andrea Benedetti; Kevin Schwartzman Journal: Ann Intern Med Date: 2008-11-18 Impact factor: 25.391
Authors: Petra Thulin; Gunnar Nordahl; Marcus Gry; Getnet Yimer; Eleni Aklillu; Eyasu Makonnen; Getachew Aderaye; Lars Lindquist; C Mikael Mattsson; Björn Ekblom; Daniel J Antoine; B Kevin Park; Stig Linder; Alison H Harrill; Paul B Watkins; Björn Glinghammar; Ina Schuppe-Koistinen Journal: Liver Int Date: 2013-10-14 Impact factor: 5.828
Authors: Aula Abbara; Sarah Chitty; Jennifer K Roe; Rohma Ghani; Simon M Collin; Andrew Ritchie; Onn Min Kon; John Dzvova; Harriet Davidson; Thomas E Edwards; Charlotte Hateley; Matthew Routledge; Jim Buckley; Robert N Davidson; Laurence John Journal: BMC Infect Dis Date: 2017-03-24 Impact factor: 3.090
Authors: Laila Parvaresh; Shopna K Bag; Jin-Gun Cho; Neil Heron; Hassan Assareh; Sophie Norton; Stephen Corbett; Ben J Marais Journal: BMJ Open Respir Res Date: 2018-10-25
Authors: Sina Helbig; Sergey Rekhtman; Kristen Dostie; Alexander Casler; Thomas Schneider; Natasha S Hochberg; Lisa Ganley-Leal Journal: Glob Vaccines Immunol Date: 2016-05-27
Authors: Jude Eteneneng Enoh; Frederick Nchang Cho; Faustin Pascal Manfo; Simon Eyongabane Ako; Eric Achidi Akum Journal: Biomed Res Int Date: 2020-05-12 Impact factor: 3.411